Matthew H Taylor

发表

Immune Checkpoint Inhibitors in Organ Transplant Patients

A. Kittai, H. Oldham, J. Cetnar, 2017, Journal of immunotherapy.

Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.

Sung-Bae Kim, M. Schlumberger, M. Brose, 2015, The New England journal of medicine.

Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced unresectable mesothelioma from the JAVELIN solid tumor phase Ib trial: Safety, clinical activity, and PD-L1 expression.

Manish R. Patel, J. Nemunaitis, A. Heydebreck, 2016 .

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Manish R. Patel, Charles J. Vaske, Joe Y. Chang, 2016, Journal for Immunotherapy of Cancer.

Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study.

A. Mansfield, Michael Thomas, R. Doebele, 2021, The Lancet. Oncology.

Efficacy and safety of first-line avelumab in patients with advanced non-small cell lung cancer: results from a phase Ib cohort of the JAVELIN Solid Tumor study

C. Redfern, K. Kelly, C. Verschraegen, 2020, Journal for ImmunoTherapy of Cancer.

The LEAP program: lenvatinib plus pembrolizumab for the treatment of advanced solid tumors.

E. Schmidt, D. Rasco, Matthew H Taylor, 2020, Future oncology.

Medical therapy for advanced forms of thyroid cancer.

U. Rajhbeharrysingh, Matthew H Taylor, M. Milas, 2014, The Surgical clinics of North America.

Safety and Efficacy of Pembrolizumab in Combination with Acalabrutinib in Advanced Head and Neck Squamous Cell Carcinoma: Phase 2 Proof-of-Concept Study

A. Jimeno, L. Coussens, J. Nemunaitis, 2021, Clinical cancer research : an official journal of the American Association for Cancer Research.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts

Amanda R. Campbell, F. Lund-Johansen, Yair Benita, 2016 .

A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti–PD-1 antibody, in patients with advanced solid tumors

J. Schellens, Sunil Sharma, A. Naing, 2020, Journal for ImmunoTherapy of Cancer.

A phase 3, multicenter, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid cancer (SELECT).

Sung-Bae Kim, M. Brose, S. Sherman, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Use of Data from Published Kaplan-Meier Survival Curves in NICE HTAs

Matthew H Taylor, K. Fleetwood, A. Yellowlees, 2013 .

Academic Cancer Center Phase I Program Development

J. Berlin, K. Flaherty, E. Frenkel, 2017, The oncologist.

Tumor immune microenvironment characteristics of papillary thyroid carcinoma are associated with histopathological aggressiveness and BRAF mutation status

L. Coussens, Matthew H Taylor, M. Shindo, 2019, Head & neck.

Open‐label, multicenter, phase 1 study of alisertib (MLN8237), an aurora A kinase inhibitor, with docetaxel in patients with solid tumors

K. Venkatakrishnan, C. Higano, N. Hahn, 2016, Cancer.

Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Patricia A. H. Williams, Steve B Jones, K. Y. Wong, 2021, The Lancet.

Clinical activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients (pts) with advanced RET-fusion+ non-small cell lung cancer (NSCLC).

Michael Thomas, R. Doebele, G. Curigliano, 2019, Journal of Clinical Oncology.

Activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients with advanced RET-altered thyroid cancers.

G. Curigliano, Dong-Wan Kim, M. Schuler, 2019, Journal of Clinical Oncology.

Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors

R. Motzer, Chung-Han Lee, D. Rasco, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial.

E. Schmidt, D. Hyman, D. Rasco, 2019, The Lancet. Oncology.

Two-year overall survival rates from a randomised phase 2 trial evaluating the combination of nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma

G. Linette, C. Horak, J. Wolchok, 2017 .

Avelumab (MSB0010718C; anti-PD-L1) in patients with recurrent/refractory ovarian cancer from the JAVELIN Solid Tumor phase Ib trial: Safety and clinical activity.

K. Kelly, G. Weiss, A. Heydebreck, 2016 .

Efficacy of Selpercatinib in RET-Altered Thyroid Cancers.

A. Drilon, M. Burkard, T. Owonikoko, 2020, The New England journal of medicine.

Safety profile of avelumab in patients with advanced solid tumors: A pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials

K. Kelly, J. Infante, N. Iannotti, 2018, Cancer.

Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with previously treated, recurrent or refractory ovarian cancer: A phase Ib, open-label expansion trial.

K. Kelly, G. Weiss, J. Infante, 2015 .

Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study.

A. Mansfield, G. Curigliano, M. Schuler, 2021, The lancet. Diabetes & endocrinology.

Lenvatinib (LEN) plus pembrolizumab (PEMBRO) for early-line treatment of advanced/recurrent endometrial cancer (EC).

E. Schmidt, J. Mier, C. Aghajanian, 2020 .

Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, for hematologic malignancies.

I. Flinn, A. Feldman, J. Nemunaitis, 2020, Blood advances.

Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032

D. Jäger, P. Ascierto, P. Ott, 2015, Journal of Immunotherapy for Cancer.

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.

G. Linette, C. Horak, J. Wolchok, 2015, The New England journal of medicine.

Correction to: 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018)

J. Taube, S. Jain, E. Schmidt, 2019, Journal of Immunotherapy for Cancer.

Fibroblast Growth Factor Signaling Controls Liver Size in Mice With Humanized Livers.

J. Darnell, M. Grompe, B. Tarlow, 2015, Gastroenterology.

Nivolumab (nivo) ± ipilimumab (ipi) in advanced small-cell lung cancer (SCLC): First report of a randomized expansion cohort from CheckMate 032.

P. Ascierto, P. Ott, M. Hellmann, 2017 .

Abstract CT127: Phase I and expanded access experience of LOXO-195 (BAY 2731954), a selective next-generation TRK inhibitor (TRKi)

B. Tuch, Alan Ho, N. Shukla, 2019, Clinical Trials.

Ferumoxytol-Enhanced MRI Is Not Inferior to Gadolinium-Enhanced MRI in Detecting Intracranial Metastatic Disease and Metastasis Size.

E. Neuwelt, Matthew H Taylor, R. Barajas, 2020, AJR. American journal of roentgenology.

Safety and Clinical Activity Of Crizotinib In Patients With ALK-Rearranged Hematologic Malignancies

K. Horibe, T. Kim, F. Braiteh, 2013 .

Phase I/II, open-label study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) as monotherapy or combined with ipilimumab in advanced or metastatic solid tumors.

P. Sharma, P. Ott, M. Callahan, 2014 .

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Steve B Jones, K. Y. Wong, Chamil H. Hettiarachchi, 2021, Lancet.

Treatment patterns, health state, and health care resource utilization of patients with radioactive iodine refractory differentiated thyroid cancer

Matthew H Taylor, A. Forsythe, N. Flores, 2016, Cancer management and research.

Precision Targeted Therapy with BLU-667 for RET-Driven Cancers.

S. Ou, C. Lengauer, Wei Hu, 2018, Cancer discovery.